Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis. (PubMed, Haematologica) - Aug 28, 2026 - "From 3/2013 to 10/2021, 61 patients were treated (median age 66 years; range, 46-87 years). By baseline blast count, 54 patients had chronic phase disease (."
Journal • P2 data • Myelofibrosis • Myeloproliferative Neoplasm • Oncology
|
|
Courtney DiNardo; Dyana Saenz; Elias Jabbour; Farhad Ravandi; Guillermo Garcia-Manero; Habiba Halim; Hagop Kantarjian; Jayastu Senapati; Jing Ning; Koichi Takahashi; Linghsa Zhou; Lucia Masarova; Maro Ohanian; Naval Daver; Naveen Pemmaraju; Nitin Jain; Prithviraj Bose; Sankalp Arora; Tapan Kadia; Victoria Chu; Yesid Alvarado
|